Publications
350 publications
Sort by: Date / Relevance
GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation
Zorginstituut Nederland has completed its assessment whether the substance levomepromazine (Nozinan®) can be included in the ...
Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)
Zorginstituut Nederland has completed its assessment whether the further conditions of SGLT-2 inhibitors canagliflozin ...
GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine
The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...
GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage
The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...
GVS advice drospirenon-estetrol (Drovelis®)
The National Health Care Institute has completed its assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with ...
Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)
Zorginstituut Nederland recommends that larotrectinib (Vitrakvi®) should be conditionally included in the basic health care ...
Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)
Zorginstituut Nederland recommends that entrectinib (Rozlytrek®) should be conditionally included in the basic health care ...
Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
The National Health Care Institute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...
GVS advice on the reassessment of tafamidis (Vyndaqel®)
The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...
Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)
The National Health Care Institute has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).